A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden

22/02/2021
26/03/2025
EU PAS number:
EUPAS39351
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

p19633-protocol abstract-pmos-04sep2020_Redacted

English (180.77 KB - PDF) View document
Updated protocol

p19633-protocol-V1.6_Abstract_Redacted

First published: 22/02/2024
English (693.4 KB - PDF) View document
Study results
Study report
Other information
Study, other information

DoI_all combined.pdf

English (295.47 KB - PDF) View document